President Message

My name is Sawa Fujita. I have been appointed as President. Inheriting the remarkable achievements of past presidents, I will strive to further advance the Japanese Society of Cancer Nursing.

Established in 1987, our society has operated with the mission of advancing research, education, and practice in cancer nursing to contribute to people’s health and welfare. In 2013, it was incorporated, growing into a leading academic organization in Japanese cancer nursing, built on a tradition of valuing nursing practice. In 2025, we celebrate our 40th anniversary. For the 40th Annual Conference, we plan a commemorative event reflecting on our 40-year history while envisioning the future of cancer nursing, aiming to shape its path forward.

In recent years, the pace of advancements in cancer diagnosis and treatment technologies has been remarkable, and since the pandemic, methods of healthcare delivery have also evolved. Meanwhile, cancer survivors are now able to live longer, but those in the extended and permanent stages face numerous challenges: physical issues such as treatment side effects and late-onset complications, psychological concerns like fear of recurrence or metastasis, social difficulties including employment and relationships, and economic burdens from costly treatments. As a result, the needs of patients and their families have become increasingly diverse and complex, with growing demands to address unmet needs. In this context, our society, with approximately 5,300 members, strives to provide patient-centered care and nursing, enabling cancer survivors and their families to live authentically with cancer in their familiar communities, with each member contributing according to their respective roles.

The following activities are implemented as the projects of JSCN based on “prevention of cancer,” “enhancement of the cancer medical treatment,” and “symbiosis with cancer,” which are the policies of each field of the Basic Plan to Promote Cancer Control Programs under the Cancer Control Act in Japan. The activities include ① holding science meetings, ② publishing journal issues, ③ improving nursing practice and research, ④ collaborating with related science groups domestically and globally, ⑤ conducting international exchange activities, and ⑥ contributing to people’s health and welfare. In 2023–2024, we focused on advancing overseas training programs for advanced practice nurses in cancer care and enhancing continuing education for nurses. Additionally, in collaboration with the Japanese Society of Clinical Oncology and the Japanese Society of Clinical Oncology Pharmacy, we published the third edition of the 2023 Joint Guidelines on Extravasation Associated with Cancer Drug Therapy and initiated revisions to existing guidelines. Moving forward, we will strengthen ties with related societies to broadly contribute to cancer care. At our academic conferences, we have partnered with patient organizations to plan and implement patient- and family-involved programs, fostering mutual learning and enriching cancer nursing, healthcare, and support for patients and families. We aim to further develop these initiatives and, in 2027, host a joint conference in Japan with the International Society of Nurses in Cancer Care (ISNCC) and the Asian Oncology Nursing Society (AONS), strengthening global networks and contributing to the advancement of cancer nursing practice in Japan.

The 2025–2026 Board of Directors is committed to making meaningful contributions to our members. Together with the board members and auditors, we will dedicate ourselves to managing the society effectively. We sincerely ask for the understanding and support of our members and all those involved in cancer care and nursing. Thank you for your kind consideration.

April,2025
Sawa Fujita, PhD, RN
President of the Japanese Society of Cancer Nursing